Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.
Zouboulis CC, Prens EP, Sayed CJ, Molina-Leyva A, Bettoli V, Romanelli M, Szepietowski JC, Martinez AL, Kasparek T, Lobach I, Wozniak MB, Ortmann CE, Thomas N, Bachhuber T, Ravichandran S, Tzellos T. Zouboulis CC, et al. Among authors: ravichandran s. J Eur Acad Dermatol Venereol. 2023 Dec 6. doi: 10.1111/jdv.19681. Online ahead of print. J Eur Acad Dermatol Venereol. 2023. PMID: 38058224 No abstract available.
Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials.
Wei X, Passera A, Muscianisi E, Uhlmann L, Chen L, Moreno SG, Martin R, Vandemeulebroecke M, Keefe D, Ravichandran S, Wozniak MB. Wei X, et al. Among authors: ravichandran s. J Am Acad Dermatol. 2023 Dec;89(6):1285-1287. doi: 10.1016/j.jaad.2023.07.1035. Epub 2023 Aug 12. J Am Acad Dermatol. 2023. PMID: 37579844 Free article. No abstract available.
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC, Passeron T, Pariser D, Wozniak MB, Li X, Uhlmann L, Lobach I, Martinez AL, Ravichandran S, Alarcon I, Offidani A, Alam MS, Mendes-Bastos P. Zouboulis CC, et al. Among authors: ravichandran s. Br J Dermatol. 2024 May 17;190(6):836-845. doi: 10.1093/bjd/ljae098. Br J Dermatol. 2024. PMID: 38470171 Clinical Trial.
Revisiting the SUNSHINE and SUNRISE trials.
Kimball AB, Ravichandran S; SUNSHINE and SUNRISE trial teams. Kimball AB, et al. Among authors: ravichandran s. Lancet. 2024 Feb 17;403(10427):616. doi: 10.1016/S0140-6736(23)02612-0. Lancet. 2024. PMID: 38368010 No abstract available.
Advanced Computational Methods for Radiation Dose Optimization in CT.
Rao S, Sharan K, Chandraguthi SG, Dsouza RN, David LR, Ravichandran S, Mustapha MT, Shettigar D, Uzun B, Kadavigere R, Sukumar S, Ozsahin DU. Rao S, et al. Among authors: ravichandran s. Diagnostics (Basel). 2024 Apr 29;14(9):921. doi: 10.3390/diagnostics14090921. Diagnostics (Basel). 2024. PMID: 38732335 Free PMC article.
Evolving radiographic practice: Identifying possible skill requirements for future radiographers practicing in the United Arab Emirates (UAE).
David LR, Elshami W, Lawal O, Panakkal N, T V, Abuzaid M, England A, McEntee M, Somasundaram T, Sukumar S, Ravichandran S, Yuvali M. David LR, et al. Among authors: ravichandran s. J Med Imaging Radiat Sci. 2024 May 7:S1939-8654(24)00048-1. doi: 10.1016/j.jmir.2024.02.018. Online ahead of print. J Med Imaging Radiat Sci. 2024. PMID: 38719647
Quantifying Putative Retinal Gliosis in Preclinical Alzheimer's Disease.
Ravichandran S, Snyder PJ, Alber J, Kenny MR, Rothstein A, Brown K, Murchison CF, Clay OJ, Roberson ED, Arthur E. Ravichandran S, et al. Invest Ophthalmol Vis Sci. 2024 May 1;65(5):5. doi: 10.1167/iovs.65.5.5. Invest Ophthalmol Vis Sci. 2024. PMID: 38696189 Free PMC article.
372 results